Singapore-based research network is appointed WHO collaborating centre for clinical trials
ADVANCE-ID will partner with other countries to better prevent, detect and control infectious diseases.
Singapore's regional research network, Advancing Clinical Evidence in Infectious Diseases (ADVANCE-ID), has been designated by the World Health Organization (WHO) as a collaborating centre to bolster high-quality clinical research in the region. The designation aims to tackle current and future public health challenges, particularly infectious diseases.
As Singapore's 13th WHO collaborating centre, ADVANCE-ID will enhance research ecosystems and collaborate with other countries to prevent, detect, and control infectious diseases, ultimately protecting Singapore's population against emerging health threats. ADVANCE-ID, based at the National University of Singapore's Saw Swee Hock School of Public Health, is the sole network globally specializing in antimicrobial resistance (AMR).
While its primary focus is on AMR, its capabilities, such as trial design and implementation, research network building, capacity building, data systems, and rapid site activation, can be applied to other infectious disease priorities and emerging health threats. The network launched in March 2022, serving as a hub for over 30 hospitals across Asia collaborating in infectious diseases clinical research.
The WHO designation acknowledges ADVANCE-ID's positive impact on the region and globally, enabling better engagement with policymakers to influence health policies.
Written by urgent.news from Straits Times's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
